CA0717341071
© ACCESSWIRE
08.12.2025
BHC
LISTED
TSX
Bausch Health Announces Early Exchange Offer Results for Exchange Offers
News Preview
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the results to date of its previously announced offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the &qu...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.12.2025
BHC
LISTED
TSX
Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China
News Preview
Transaction boosts Solta Medical's position to meet rising demand in China's growing aesthetics market LAVAL, QC / ACCESS Newswire / December 1, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, along with its global aesthetic business, Solta Medical, today announced the successful completion of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.11.2025
BHC
LISTED
TSX
Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
News Preview
LAVAL, QC / ACCESS Newswire / November 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced the commencement of offers to exchange the Company's outstanding 4.875% Senior Secured Notes due 2028 (the "4.875% Notes") and 11.00% Senior Secured Notes due 2028 (the &...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
18.11.2025
BHC
LISTED
TSX
Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
News Preview
LAVAL, QC / ACCESS Newswire / November 18, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025. A live audio webcast o...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
05.11.2025
BHC
LISTED
TSX
Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
News Preview
Expansion improves access to treatment options within periodontal care and helps strengthen partnerships with dental professionals within these populations. LAVAL, QC / ACCESS Newswire / November 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company, and OraPharma, its dental products business, toda...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.10.2025
BHC
LISTED
TSX
Bausch Health Announces Third Quarter 2025 Results
News Preview
Third Quarter Consolidated Revenues of $2.68 billion, up 7% on a Reported basis and 5% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health of $179 million and GAAP Net Income of $181 millionConsolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $986 million, including an $81 mil...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.10.2025
BHC
LISTED
TSX
Bausch Health Announces Results of Special Meeting of Shareholders
News Preview
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the results of the special meeting of shareholders held on October 7, 2025 (the "Shareholders Meeting"). At the Shareholders Meeting, shareholders of the Company approved the ratification, confirmation...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.09.2025
BHC
LISTED
TSX
Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
News Preview
The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appearance while enhancing natural beauty. LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.09.2025
BHC
LISTED
TSX
Bausch Health to Announce Third Quarter 2025 Results on October 29
News Preview
LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025. Bausch Health will host a live conference call and webcast at 5:00 p.m. U.S. EDT to discuss results and provide a business update. All materials will...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.09.2025
BHC
LISTED
TSX
Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
News Preview
Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue.Nine-episode inaugural season hosted by industry thought leader Melissa K. Turner, BASDH, RDHEP, EFDA, CHO.Candid conversations with leading clinicians on the trends shaping today's dental landscape.Episodes launch on September 29 on major...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.09.2025
BHC
LISTED
TSX
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
News Preview
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND CUPERTINO, CA / ACCESS Newswire / September 11, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), a glo...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.09.2025
BHC
LISTED
TSX
Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
News Preview
LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, today announced that the Company's proven Thermage technology has successfully been used to perform more than 5 million skin tightening...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
26.08.2025
BHC
LISTED
TSX
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
News Preview
LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) today announced that BHC Lyon Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Bausch Health Americas, Inc. ("BHA"), an...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.08.2025
BHC
LISTED
TSX
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
News Preview
LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.08.2025
BHC
LISTED
TSX
Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
News Preview
LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and managed funds have increased their ownership of the Company's common shares.The increase reflects the acquisition by Paulson Capi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.08.2025
BHC
LISTED
TSX
Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
News Preview
For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2025 Salix Gastroi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.07.2025
BHC
LISTED
TSX
Bausch Health Announces Second Quarter 2025 Results
News Preview
Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health Companies of $148 million and GAAP Net Income of $128 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP)1 of $842 million,...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.07.2025
BHC
LISTED
TSX
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
News Preview
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic hepatitisProposed acquisition strengthens Bausch Health's commitment to hepatology and patients suffering with liver disease complications glob...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
28.07.2025
BHC
LISTED
TSX
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
News Preview
LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., has issued an irrevocable notice of redemption pursuant to which it will redeem approximately $602 million of aggregate principal a...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.07.2025
BHC
LISTED
TSX
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
News Preview
LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sandra Leung to its Board of Directors, effective July 22, 2025. The appointments increase the size of the Board from ten to twelve members.Michael Goet...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.07.2025
BHC
LISTED
TSX
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
News Preview
This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.07.2025
BHC
LISTED
TSX
Bausch Health Appoints New Chief Accounting Officer
News Preview
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vice President, Controller and Chief Accounting Officer, effective Monday, July 14.Steven brings extensive experience in financial transformation, merge...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.07.2025
BHC
LISTED
TSX
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
News Preview
LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug pl...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.07.2025
BHC
LISTED
TSX
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
News Preview
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced its...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.07.2025
BHC
LISTED
TSX
Bausch Health to Announce Second Quarter 2025 Results on July 30
News Preview
LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. All materials will be...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.05.2025
BHC
LISTED
TSX
Bausch Health Announces 2025 Annual Meeting of Shareholder Results
News Preview
LAVAL, QC / ACCESS Newswire / May 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the election of the 10 directors nominated at its 2025 annual meeting of shareholders ("Annual Meeting") held on May 13, 2025. The detailed results of the vote for the election of directors are set out below:Name For Withheld Brok...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.05.2025
BHC
LISTED
TSX
Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization
News Preview
New analysis suggests efficacy of Xifaxan to mitigate OHE rehospitalizations irrespective of treatment history LAVAL, QC / ACCESS Newswire / May 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.04.2025
BHC
LISTED
TSX
Bausch Health Announces First Quarter 2025 Results
News Preview
First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year periodGAAP Net Loss Attributable to Bausch Health Companies of $58 million and GAAP Net Loss of $86 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies (non-GAAP) 1 of $661 million, in l...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.04.2025
BHC
LISTED
TSX
Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System
News Preview
A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetic business, Solta Medical, announced today that Health Canada has granted med...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.04.2025
BHC
LISTED
TSX
Bausch Health Announces Launch of Solta Medical's Fraxel FTX(TM)
News Preview
The next generation of skin resurfacing technology will debut at the ASLMS 2025 Conference LAVAL, QC / ACCESS Newswire / April 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its aesthetics business, Solta Medical, announced today Fraxel FTX™ will launch at the American Society fo...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.04.2025
BHC
LISTED
TSX
Bausch Health Announces Filing of Supplement to Proxy Statement
News Preview
Supplement In Response to Company Learning that Carl Icahn and Affiliates Have Cash-Settled Equity Swaps for Approximately 90 Million of Its Common Shares LAVAL, QC / ACCESS Newswire / April 22, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX: BHC) (the "Company" or "Bausch Health") today announced that it has filed a supplem...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.04.2025
BHC
LISTED
TSX
U.S. District Court Grants Summary Judgment in Favor of FDA, Salix, and Teva, and Against Norwich
News Preview
LAVAL, QC / ACCESS Newswire / April 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), and its gastroenterology business Salix Pharmaceuticals, Inc., today announced the U.S. District Court for the District of Columbia in the matter of Norwich Pharmaceuticals, Inc. v. Kennedy, et al....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.04.2025
BHC
LISTED
TSX
Bausch Health Announces Adoption of Shareholder Rights Plan
News Preview
LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") announces today that its board of directors (the "Board") has approved the adoption of a shareholder rights plan (the "SRP") pursuant to a shareholder rights plan agreement entere...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.04.2025
BHC
LISTED
TSX
Bausch Health Announces Ortho Dermatologics 2025 ASPIRE HIGHER Scholarship Program
News Preview
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with application submissions open through June 11, 2025 LAVAL, QC / ACCESS Newswire / April 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)and its dermatology business, Ortho Dermatologics, today announced the 2025 ASPIRE HIGHER Scholarship Progr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.04.2025
BHC
LISTED
TSX
Bausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance Sign Letter of Intent for Public Drug Plan Coverage of (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris
News Preview
LAVAL, QC / ACCESS Newswire / April 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for Canadian public drug plan coverage for PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) g...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.04.2025
BHC
LISTED
TSX
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
News Preview
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated. LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) busines...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.03.2025
BHC
LISTED
TSX
Bausch Health to Announce First Quarter Results on April 30
News Preview
LAVAL, QC / ACCESS Newswire / March 27, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter financial results after market close on Wednesday, April 30, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EDT to discuss the results and provide a business update. All materials will be mad...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.03.2025
BHC
LISTED
TSX
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
News Preview
LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes&qu...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.03.2025
BHC
LISTED
TSX
Bausch Health Announces Conditional Redemption of Senior Notes
News Preview
LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.03.2025
BHC
LISTED
TSX
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
News Preview
LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirec...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.03.2025
BHC
LISTED
TSX
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
News Preview
Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndicat...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.03.2025
BHC
LISTED
TSX
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
News Preview
LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P. Morgan in connection with the Comp...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.02.2025
BHC
LISTED
TSX
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
News Preview
Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidanceFourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
14.02.2025
BHC
LISTED
TSX
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
News Preview
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's web...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.02.2025
BHC
LISTED
TSX
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
News Preview
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program appl...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.02.2025
BHC
LISTED
TSX
Bausch Health Provides Update on Strategic Alternatives
News Preview
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.01.2025
BHC
LISTED
TSX
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
News Preview
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.01.2025
BHC
LISTED
TSX
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
News Preview
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiatio...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
12.12.2024
BHC
LISTED
TSX
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
News Preview
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Inv...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.12.2024
BHC
LISTED
TSX
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
News Preview
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united t...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
02.12.2024
BHC
LISTED
TSX
Bausch Health Appoints New Chief Medical Officer and Head of R&D
News Preview
LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching li...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.11.2024
BHC
LISTED
TSX
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
News Preview
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical tr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.11.2024
BHC
LISTED
TSX
PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS
News Preview
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.10.2024
BHC
LISTED
TSX
Bausch Health Announces Third Quarter 2024 Results
News Preview
Sixth consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1Third quarter consolidated revenues of $2.51 billion, up 12% on a Reported basis and 9% on an Organic (non-GAAP)1 basis, with growth in all segmentsConsolidated GAAP Net Loss Attributable to Bausch Health Companies Inc. of $85 millionConsolidated Adjus...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.10.2024
BHC
LISTED
TSX
ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence
News Preview
Additional ACG presentation to focus on impact of Xifaxan on OHE rehospitalizationsLAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an analysis of Xifaxan® (rifaximin) monotherapy will be pres...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.10.2024
BHC
LISTED
TSX
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
News Preview
LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. All materials will be...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.10.2024
BHC
LISTED
TSX
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
News Preview
Findings show care for chronic liver disease patients is falling on non-specialists who need stronger education and support to ensure patients receive timely, optimal care1LAVAL, QC / ACCESSWIRE / October 8, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), tod...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
